HomeInvestors HealthNeurocrine upped to overweight by Piper, sees '568 as still viable

Neurocrine upped to overweight by Piper, sees '568 as still viable

525-5250815_gold-ball-free-png-gold-ball-png-clipart

August 29, 2024

Neurocrine upped to overweight by Piper, sees '568 as still viable

Source link

Previous article

2 Cathie Wood Stocks That Are Top Buys for Long-Term Investors

Next article

Palantir Is a Top Artificial Intelligence (AI) Stock. Is This Its Achilles’ Heel?

Investors Health Image

latest articles

explore more

LEAVE A REPLY Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here